| Head and Neck Cutaneous Carcinoma studied in …STUDIED_INderived10 of 55show all (up to 200) |
|---|
| → studied in | NCT06589804Phase 3 · recruiting Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05878288Phase 2 · active not recruiting Deep sequencIng in Cutaneous Squamous CEll caRciNomas · condition mapped ALIAS · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07576725Phase 2 · not yet recruiting Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05721755Phase 3 · active not recruiting Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07156227Phase 1 · recruiting Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06568172Phase 3 · suspended Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer · condition mapped ONTOLOGY_EXACT · 55 trials mapped (27 active) | — | — | Eyelid Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06990737Phase 2 · withdrawn Phase 2 Pragmatic Trial of Sentinel Lymph Node Biopsy (SLNB) in Patients With Clinically Node-Negative (cN0), High-Risk Cutaneous Squamous Cell Carcinoma (cSCC) of the Head and Neck · condition mapped ALIAS · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04576091Phase 1 · active not recruiting Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05269381Phase 1/Phase 2 · recruiting Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06532279Phase 2 · recruiting Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer · condition mapped CURATED_BROADER · 55 trials mapped (27 active) | — | — | Head and Neck Cutaneous Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |